Desvenlafaxine:一个新的serotonin-norepinephrine再摄取抑制剂用于治疗成人重度抑郁症。

文章的细节

引用

复制到剪贴板

Perry R, Cassagnol M

Desvenlafaxine:一个新的serotonin-norepinephrine再摄取抑制剂用于治疗成人重度抑郁症。

其他。2009年6月,31日Pt 1:1374 - 404。doi: 10.1016 / j.clinthera.2009.07.012。

PubMed ID

19698900 (在PubMed

]

文摘

背景:Desvenlafaxine琥珀酸,serotonin-norepinephrine再摄取抑制剂(去甲肾上腺素重摄取抑制剂),是经美国食品和药物管理局(FDA)在2008年2月治疗成人重度抑郁症患者(MDD)。Desvenlafaxine第三SNRI FDA批准的迹象。目的:本文综述为desvenlafaxine可用的信息,关注其药效学、药代动力学、临床疗效、安全性及。方法:全面搜索MEDLINE(1950 - 200必威国际app9年3月),国际制药抽象(1970 - 2009年3月),ISI的网络知识(1996 - 2009年3月),和EMBASE(1974 - 2009年3月)进行了使用条款desvenlafaxine O-desmethylvenlafaxine, Pristiq。参考列表文章综述了其他相关的出版物。抽象的未发表的临床研究发表在美国精神病学协会年会(2004 - 2008)被包括在审查;还包括了数据来自美国食品和药物管理局和欧洲药品局网站。结果:口服后,desvenlafaxine达到T (max)在7到8小时,慢慢消除,与T((1/2))值9到15个小时。每天换一次剂量,稳态血浆浓度在4到5天内完成。应该实现隔日给药有严重肾功能损害的患者(肌酐清除率,<或= 30毫升/分钟)和终末期肾病。 In patients with moderate to severe hepatic impairment, daily doses should not exceed 100 mg. Nine short-term studies of desvenlafaxine have been conducted but only 8 were published. These 8 clinical studies evaluated oral desvenlafaxine 50 to 400 mg/d using randomized controlled trials for the treatment of MDD in adult outpatients. Significantly greater efficacy in the reduction of depressive symptoms was found in patients taking desvenlafaxine 50 mg/d (P < 0.05) compared with placebo. No additional therapeutic benefits were found at doses >50 mg/d. Preliminary data support desvenlafaxine's efficacy and tolerability in the treatment of menopause-associated vasomotor symptoms. Desvenlafaxine was generally well tolerated in clinical trials; the most common adverse events were nausea, suicidal ideation, and changes in blood pressure and weight. CONCLUSIONS: Desvenlafaxine 50 mg/d has been found to be efficacious and generally well tolerated in short-term trials for the treatment of adults with MDD. Further studies are needed to determine des-venlafaxine's role in the management of MDD and its efficacy compared with other antidepressants.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Desvenlafaxine	Sodium-dependent去甲肾上腺素转运体	蛋白质	人类	是的	抑制剂	细节
Desvenlafaxine	Sodium-dependent羟色胺转运体	蛋白质	人类	是的	抑制剂	细节